Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer

Table 1 Characteristics of the study participants

	Experimental group	Control group	p value
Cases, n	4	13	–
Rectal cancer, n	2	6	0.89
Males, n	3	8	0.62
Age (years)	63.88 ± 8.61	64.23 ± 8.76	0.94
BMI (kg/m²)	22.74 ± 2.64	23.28 ± 2.43	0.71
Long-term smoking history, n	0	1	0.57
Long-term drinking history, n	1	4	0.82
Known diabetes, n	0	1	0.57
Known hypertension, n	0	0	/
Hemoglobin (g/L)	134.25 ± 5.06	124.62 ± 13.71	0.20
Alanine transaminase (U/L)	29.00 ± 30.97	19.80 ± 8.94	0.33
Glutamic oxaloacetic transaminase (U/L)	27.40 ± 15.78	24.56 ± 8.72	0.64
Albumin (g/L)	42.03 ± 4.57	38.11 ± 3.02	0.06
Creatinine (μmol/L)	83.10 ± 33.74	68.95 ± 14.66	0.24
Carbohydrate antigen 199 (U/mL)	5.46 ± 3.61	12.24 ± 9.36	0.18
Carbohydrate antigen 742 (U/mL)	8.58 ± 3.61	9.89 ± 19.71	0.90
Carcino embryonic antigen (ng/mL)	24.34 ± 41.47	3.98 ± 3.70	0.08

Overall, 17 resected stage III CRC patients undergoing the CapeOX regimen were recruited. These patients were divided into experimental group (CID+) and control group (CID−) according to whether they had diarrhea or not. The patient’s clinical information was shown in thus table. The clinical stages conformed to the criterion of stage III CRC according to AJCC. Smoking and drinking history over the course of 1 year were collected. Blood samples of patients before chemotherapy were collected for serological examination

ISSN: 1757-4749